From the helm: Proteomics International (ASX:PIQ), Dr. Richard Lipscombe, Managing Director

Bell Direct
July 7, 2025

In this episode of From the helm, Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics and the global opportunity for its world-first blood tests.

In this video, Dr. Lipscombe covers:
·      (0:47): An overview of PIQ and its FY26 goals
·      (1:38): The significance of three world-first blood tests
·      (5:26): The global addressable markets for these conditions
·      (6:25): Clinical trial progress and commercialisation roadmap
·      (8:14): How the diagnostic tests work and deliver value to patients
·      (9:16): Commercialisation strategy across key regions
·      (11:23): Additional assets in the PIQ pipeline
·      (12:36): What investors can expect over the next 12 months

Note: This interview was recorded on 3 July 2025.

Market Update

Julia Lee
December 5, 2016

Market Update

Julia Lee
December 2, 2016

Market Update

Julia Lee
December 1, 2016

2016 Overview

Julia Lee
November 28, 2016

Market Update

Julia Lee
November 17, 2016

Peter Quinton on Trump’s victory

Bell Direct
November 17, 2016

Bell Potter: Banks post-results review

Bell Direct
November 11, 2016

mFund series: Peters MacGregor

Bell Direct
October 11, 2016

mFund series: RARE Infrastructure

Bell Direct
October 11, 2016

Bell Potter: Five standout stocks

Bell Direct
October 7, 2016